Czy wysoki cholesterol powoduje miażdżycę?

*WESPRZYJ NA PATRONITE*: https://patronite.pl/dr-damian-parol SEGMENTY: 00:00 Wstęp 02:01 ApoB 04:09 Dowody mechanistyczne 04:42 Badania na zwierzętach 05:46 Badania obserwacyjne 07:02 Czemu nie mamy eksperymentów? 08:10 Badania z randomizacją mendlowską 10:41 Leki obniżające LDL 12:02 Stan zapalny LINKI: Blog: https://www.damianparol.com/ Zapis na newsletter: https://www.damianparol.com/newsletter/ Facebook:   / damian.parol   Instagram:   / dr.damian.parol   Threads: https://www.threads.com/@dr.damian.parol Twitter:   / paroldamian   TikTok:   / dr.damian.parol   Szkolenia on-line: https://www.warsztatnauki.pl/ Realizacja: Natalia Parol Źródła: Borén J, Chapman MJ, Krauss RM, et al. Low-density lipoproteins cause atherosclerotic cardiovascular disease: pathophysiological, genetic, and therapeutic insights. Eur Heart J. 2020;41:2313–2330. Soffer DE, Marston NA, Maki KC, et al. Role of apolipoprotein B in the clinical management of cardiovascular risk in adults. J Clin Lipidol. 2024;18:e647–e663. Główny Urząd Statystyczny. Trwanie życia w 2024 r. Warszawa: GUS; 2025. Mendieta G, Pocock S, Mass V, et al. Determinants of progression and regression of subclinical atherosclerosis over 6 years. J Am Coll Cardiol. 2023;82:2069–2083. Koskinen JS, Kytö V, Juonala M, et al. Childhood dyslipidemia and carotid atherosclerotic plaque in adulthood. J Am Heart Assoc. 2023;12:e027586. Ference BA, Yoo W, Alesh I, et al. Effect of long-term exposure to lower low-density lipoprotein cholesterol beginning early in life on the risk of coronary heart disease. J Am Coll Cardiol. 2012;60:2631–2639. Gu J, Khoury A, Qin P, et al. Modelling the potential long-term survival benefit of evinacumab treatment vs standard of care in patients with homozygous familial hypercholesterolaemia. Eur J Prev Cardiol. 2023;30:1874–1880. Cuchel M, Raal FJ, Hegele RA, et al. 2023 update on European Atherosclerosis Society consensus statement on homozygous familial hypercholesterolaemia. Eur Heart J. 2023;44:2277–2291. Wiegman A, et al. Familial hypercholesterolaemia in children and adolescents: a European Atherosclerosis Society consensus statement. Eur Heart J. 2026;47:3324–3364. Silverman MG, Ference BA, Im K, et al. Association between lowering LDL-C and cardiovascular risk reduction among different therapeutic interventions. JAMA. 2016;316:1289–1297. Ridker PM, Everett BM, Thuren T, et al. Antiinflammatory therapy with canakinumab for atherosclerotic disease. N Engl J Med. 2017;377:1119–1131. Kaplan H, Thompson RC, Trumble BC, et al. Coronary atherosclerosis in indigenous South American Tsimane. Lancet. 2017;389:1730–1739. Paramsothy P, Knopp RH, Bertoni AG, et al. Association of combinations of lipid parameters with carotid intima-media thickness and coronary artery calcium in MESA. J Am Coll Cardiol. 2010;56:1034–1041. Gautschi M, Pavlovic M, Nuoffer JM. Fatal myocardial infarction at 4.5 years in a case of homozygous familial hypercholesterolaemia. JIMD Rep. 2012;2:45–50.